cycloalkenylene, substituted or unsubstituted C_4-C_{20} cycloalkynylene, substituted or unsubstituted 3- to 6-membered heterocycloalkylene, substituted or unsubstituted C_7-C_{20} cycloalkylalkylene, substituted or unsubstituted 3- to 6-membered heterocycloalkyl-C_1-C_{20} alkylene, substituted or unsubstituted C_4-C_{20} arylene, substituted or unsubstituted C_5-C_{20} arylalkylene, substituted or unsubstituted 5- to 15-membered heteroarylene, or substituted or unsubstituted 5- to 15-membered heteroaryl-C_1-C_{20} alkylene (the groups optionally comprise one or more heteroatoms, an amide group (-CO-NH-), an ester group (-CO-O-), or a urethane group (-O-CO-NH-)), an amide group (-CO-NH-), an ester group (-CO-O-), or a urethane group (-O-CO-NH-), wherein when a plurality of R^3, $R^{3'}$ or $R^{3''}$ are present, the plurality of R^3, $R^{3'}$ or $R^{3''}$ are the same as or different from each other, and

* is a binding position to the other moieties,

or a salt thereof, or a hydrate thereof.

13. A pharmaceutical composition comprising the compound according to any one of claims 1 to 10 and 12 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof and one or more pharmaceutically acceptable carriers.

14. The pharmaceutical composition of claim 13 for use in therapy.

15. Use of the compound according to any one of claims 1 to 10 and 12 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof for manufacturing a medicament for the prevention or treatment of a cardiovascular disease, an inflammatory disease, or a peripheral vascular disease.